Seizure : the journal of the British Epilepsy Association, volume 13, pages S5-S9

Zonisamide: chemistry, mechanism of action, and pharmacokinetics

Publication typeJournal Article
Publication date2004-12-01
Quartile SCImago
Q2
Quartile WOS
Q3
Impact factor3
ISSN10591311, 15322688
General Medicine
Neurology
Neurology (clinical)
Abstract
Zonisamide is a synthetic 1,2-benzisoxazole-3-methanesulfonamide with anticonvulsant properties. The sulfamoyl group on zonisamide was expected to suppress seizures in a manner similar to another sulfonamide analogue, acetazolamide, through inhibition of carbonic anhydrase. However, this does not appear to be the primary mechanism of action since zonisamide requires much higher doses than acetazolamide to achieve equivalent titration in vivo. Studies with cultured neurons indicate that zonisamide blocks repetitive firing of voltage-sensitive sodium channels and reduces voltage-sensitive T-type calcium currents without affecting L-type calcium currents. Its dual mechanism of action may explain its efficacy in patients resistant to other antiepileptic drugs (AEDs). Zonisamide has a pharmacokinetic profile favorable for clinical use. It is rapidly and completely absorbed and has a long half-life (63-69h in healthy volunteers) which allows twice-daily, or even once-daily, dosing. Zonisamide is not highly bound to plasma proteins. Consequently, it does not affect protein binding of other highly protein-bound AEDs. Furthermore, zonisamide does not induce its own metabolism and does not induce liver enzymes. However, since zonisamide is metabolized by cytochrome P450, liver enzyme-inducing AEDs will increase zonisamide clearance, and dosage adjustments may be necessary when it is used in combination with certain AEDs.

Top-30

Citations by journals

1
2
3
4
5
6
Epilepsy Research
6 publications, 3.55%
Cochrane Database of Systematic Reviews
6 publications, 3.55%
Seizure : the journal of the British Epilepsy Association
5 publications, 2.96%
Journal of Medicinal Chemistry
4 publications, 2.37%
Expert Opinion on Drug Metabolism and Toxicology
4 publications, 2.37%
Frontiers in Neurology
3 publications, 1.78%
European Journal of Medicinal Chemistry
3 publications, 1.78%
Bioorganic and Medicinal Chemistry Letters
3 publications, 1.78%
Expert Review of Neurotherapeutics
3 publications, 1.78%
Expert Opinion on Drug Safety
3 publications, 1.78%
Expert Opinion on Pharmacotherapy
3 publications, 1.78%
Neurochemical Research
2 publications, 1.18%
CNS Drugs
2 publications, 1.18%
Acta Neurologica Belgica
2 publications, 1.18%
BMC Veterinary Research
2 publications, 1.18%
Epilepsy and Behavior
2 publications, 1.18%
Seminars in Dialysis
2 publications, 1.18%
Headache
2 publications, 1.18%
Epilepsia
2 publications, 1.18%
Organic Letters
2 publications, 1.18%
ACS Chemical Neuroscience
2 publications, 1.18%
Acta Neurologica Scandinavica
2 publications, 1.18%
Mendeleev Communications
1 publication, 0.59%
Annals of Clinical and Translational Neurology
1 publication, 0.59%
Journal of the Acoustical Society of America
1 publication, 0.59%
Journal of Pharmacology and Experimental Therapeutics
1 publication, 0.59%
Pharmacological Reviews
1 publication, 0.59%
Current Medicinal Chemistry
1 publication, 0.59%
Clinical Science
1 publication, 0.59%
1
2
3
4
5
6

Citations by publishers

5
10
15
20
25
30
35
40
Elsevier
40 publications, 23.67%
Springer Nature
24 publications, 14.2%
Wiley
23 publications, 13.61%
Taylor & Francis
16 publications, 9.47%
American Chemical Society (ACS)
8 publications, 4.73%
Wolters Kluwer Health
5 publications, 2.96%
SAGE
5 publications, 2.96%
Bentham Science
4 publications, 2.37%
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 2.37%
Frontiers Media S.A.
4 publications, 2.37%
American Society for Pharmacology and Experimental Therapeutics
2 publications, 1.18%
Royal Society of Chemistry (RSC)
2 publications, 1.18%
Dove Medical Press
2 publications, 1.18%
Mark Allen Group
2 publications, 1.18%
Acoustical Society of America (ASA)
1 publication, 0.59%
Portland Press
1 publication, 0.59%
Thieme
1 publication, 0.59%
Medknow Publications
1 publication, 0.59%
Scientific Research Publishing
1 publication, 0.59%
Korean Neurological Association
1 publication, 0.59%
Oxford University Press
1 publication, 0.59%
American Medical Association (AMA)
1 publication, 0.59%
Media Sphere Publishing Group
1 publication, 0.59%
5
10
15
20
25
30
35
40
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Leppik I. E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics // Seizure : the journal of the British Epilepsy Association. 2004. Vol. 13. p. S5-S9.
GOST all authors (up to 50) Copy
Leppik I. E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics // Seizure : the journal of the British Epilepsy Association. 2004. Vol. 13. p. S5-S9.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.seizure.2004.04.016
UR - https://doi.org/10.1016/j.seizure.2004.04.016
TI - Zonisamide: chemistry, mechanism of action, and pharmacokinetics
T2 - Seizure : the journal of the British Epilepsy Association
AU - Leppik, Ilo E.
PY - 2004
DA - 2004/12/01 00:00:00
PB - Elsevier
SP - S5-S9
VL - 13
SN - 1059-1311
SN - 1532-2688
ER -
BibTex
Cite this
BibTex Copy
@article{2004_Leppik,
author = {Ilo E. Leppik},
title = {Zonisamide: chemistry, mechanism of action, and pharmacokinetics},
journal = {Seizure : the journal of the British Epilepsy Association},
year = {2004},
volume = {13},
publisher = {Elsevier},
month = {dec},
url = {https://doi.org/10.1016/j.seizure.2004.04.016},
pages = {S5--S9},
doi = {10.1016/j.seizure.2004.04.016}
}
Found error?